This morning ImmunoPrecise Antibodies Ltd (TSXV: IPA) announced they have commenced the application process to dual list their stock on the NASDAQ. In the news release, the company states they believe the move will gain greater exposure for the company to access a larger base of retail and institutional investors in the United States and internationally.
ImmunoPrecise is a full-service, therapeutic antibody discovery company utilizing species agnostic, multi-format, characterized and engineered, human monoclonal antibodies, on an abbreviated timeframe. IPA has developed a technology platform with end-to-end solutions empowering companies to discover and develop therapies against any disease. Their full-service capabilities reduce the time and risk associated with conventional multi-vendor product development.
The company has been working on COVID by identifying antibodies derived from multiple species (human, llama, Ligand’s humanized OmniRat, and wild-type rabbits) which demonstrate potent, in vitro neutralizing activity. They have discovered their functional antibodies using the Company’s DeepDisplay phage technology, B Cell Select and Single Step Hybridoma platforms.
At the time of publishing IPA stock is trading at $1.85 an increase of 3.9%.
Sponsored · McLaren Resources Inc.
Information for this analysis was found via Sedar and ImmunoPrecise Antibodies Ltd. The author is long common shares of ImmunoPrecise Antibodies (IPA.v). Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
